Latest & greatest articles for famotidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on famotidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on famotidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for famotidine

1. Famotidine

Famotidine Top results for famotidine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for famotidine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Randomised controlled trial: Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone

Randomised controlled trial: Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic upper GI ulcers compared with ibuprofen alone Article Text Therapeutics Randomised controlled trial Single-tablet double-dose famotidine plus ibuprofen decreases endoscopic

Evidence-Based Medicine (Requires free registration)2013

3. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. 19577798 2009 07 14 2009 07 31 2015 06 16 1474-547X 374 9684 2009 Jul 11 Lancet (London, England) Lancet Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. 119-25 10.1016/S0140-6736(09)61246-0 (...) There are few therapeutic options for the prevention of gastrointestinal mucosal damage caused by low-dose aspirin. We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor antagonist, in the prevention of peptic ulcers and erosive oesophagitis in patients receiving low-dose aspirin for vascular protection. Adult patients (aged >/=18 years) from the cardiovascular, cerebrovascular, and diabetes clinics at Crosshouse Hospital, Kilmarnock, UK, were eligible for enrolment

Lancet2009

4. Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain

Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal pain Article Text Therapeutics Review: famotidine, pizotifen, cognitive behavioural therapy, and peppermint may be effective in recurrent abdominal

Evidence-Based Medicine (Requires free registration)2004

5. [FAMOTIDINE VERSUS PLACEBO IN NON ULCER DYSPEPSIA TREATMENT]

[FAMOTIDINE VERSUS PLACEBO IN NON ULCER DYSPEPSIA TREATMENT] 12140583 2002 07 25 2002 07 25 1609-722X 20 3 2000 Jul-Sep Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru Rev Gastroenterol Peru [FAMOTIDINE VERSUS PLACEBO IN NON ULCER DYSPEPSIA TREATMENT] 213-228 BACKGROUND: Non ulcer dyspepsia is an important health problem with a very high prevalence in the general population, being its pathophysiology still unclear and its association with H (...) . pylori highly controversial. Many trials have been carried out assessing the effects of different drugs on the symptoms in dyspeptic patients, being one of the most common the use of H2 antagonist, even though the results have shown conflicting as far as efficacy is concerned. The goal of the present study is to determine the efficacy of famotidine (administered in three different regimens) as compared to placebo in relieving the symptoms of non ulcer dyspepsia.METHODS: Patients with chronic non

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru2002

6. Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation

Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation Switching the histamine H2 receptor antagonist famotidine to non-prescription status in Canada: an economic evaluation Tasch R, Goeree R, Henke C, O'Brien B Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Histamine H2 Receptor Antagonist (H2RA) famotidine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical cohort of patients with heartburn and non-ulcer dyspepsia. Setting The practice setting was primary care. The economic

NHS Economic Evaluation Database.1996

7. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial.

Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. 8618369 1996 06 07 1996 06 07 2016 10 17 0098-7484 275 18 1996 May 08 JAMA JAMA Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. 1428-31 To compare an over-the-counter histamine2-receptor antagonist with an antacid as gastric acid reducers. Randomized (...) , double-blind, placebo-controlled crossover trial. Gastric secretory research laboratory in a Veterans Affairs medical center. Eighteen healthy volunteers (10 men and 8 women) aged 25 to 62 years with normal gastric acid secretion rates. The subjects received the histamine2-receptor antagonist famotidine (Pepcid AC, 10 mg), calcium carbonate antacid tablets (Tums, 1000 mg), or placebo medications 1 hour after a test meal. Two identical meals were taken 2.5 and 6.0 hours after the medication was given

JAMA1996

8. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. 8618582 1996 06 13 1996 06 13 2013 11 21 0028-4793 334 22 1996 May 30 The New England journal of medicine N. Engl. J. Med. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. 1435-9 Acid suppression with famotidine, a histamine H2-receptor antagonist, provides protection against gastric injury in normal subjects receiving short (...) courses of aspirin or naproxen. The efficacy of famotidine in preventing peptic ulcers in patients receiving long-term therapy with nonsteroidal antiinflammatory drugs (NSAIDs) is not known. We studied the efficacy of two doses of famotidine (20 mg and 40 mg, each given orally twice daily), as compared with placebo, in preventing peptic ulcers in 285 patients without peptic ulcers who were receiving long-term NSAID therapy for rheumatoid arthritis (82 percent) or osteoarthritis (18 percent

NEJM1996

9. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Poynard T, Lemaire M, Agostini H Authors' objectives To compare the clinical efficacy (...) of lansoprazole with the efficacies of ranitidine and famotidine. Searching The trials were identified using a MEDLINE search, a review of gastroenterology journals and from the files of two pharmaceutical companies (Houde and Takeda). Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Lansoprazole at the usual dose of 30 mg compared with famotidine (4 0mg) or ranitidine (300 mg). Participants

DARE.1995

10. Safety and cost of rapid IV injection of famotidine in critically ill patients

Safety and cost of rapid IV injection of famotidine in critically ill patients Safety and cost of rapid IV injection of famotidine in critically ill patients Safety and cost of rapid IV injection of famotidine in critically ill patients Fish D N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of histamine H2-receptor antagonists (H2RAs) (specifically famotidine) administered intravenously to patients in intensive care units. Type of intervention Treatment Economic study type Cost-effectiveness analysis. Study population Patients admitted to a coronary care or ICU who received at least one dose of famotidine injection as part of their treatment. Setting Hospital. The economic study was carried out in Denver, Colorado

NHS Economic Evaluation Database.1995

11. Continuous intravenous famotidine for haemorrhage from peptic ulcer.

Continuous intravenous famotidine for haemorrhage from peptic ulcer. 1357453 1992 11 23 1992 11 23 2015 06 16 0140-6736 340 8827 1992 Oct 31 Lancet (London, England) Lancet Continuous intravenous famotidine for haemorrhage from peptic ulcer. 1058-62 Peptic ulcer bleeding often stops spontaneously but rebleeding may be catastrophic. Emergency surgery carries risks so safe medical therapies are needed. Since platelet function and plasma coagulation are both pH sensitive and since pepsin lyses (...) clot at low pH the maintenance of gastric pH close to neutrality might influence rebleeding rates. Previous trials with H2 antagonists have been inadequate although a 1985 meta-analysis did support an important clinical effect. We report here a large multicentre trial of famotidine in ulcer bleeding. 1005 patients admitted to one of sixty-seven hospitals in the UK or Eire with haemorrhage from peptic ulcer with endoscopic signs of oozing, black slough, fresh clot or visible vessel were randomly

Lancet1992